/Dexcom%20headquarters%20building%20By%20MichaelVi.jpeg)
Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.
Although Danaher has underperformed relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.
/Cencora%20Inc_%20HQ-by%20JHVEPhoto%20via%20iStock.jpg)
Cencora has underperformed the broader market over the past year, yet analysts remain highly bullish about the stock’s prospects.
Though Edwards Lifesciences has underperformed the broader market over the past year, Wall Street analysts maintain a strongly optimistic outlook on the stock’s prospects.
/DaVita%20Inc%20location-%20by%20sanfel%20via%20iStock.jpg)
Though DaVita has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.
/Logo%20of%20UNITEDHEALTH%20GROUP%20By%20Alexey%20Novikov.jpeg)
UnitedHealth Group has outpaced the broader market over the past year, and analysts remain highly bullish about the stock’s prospects.
/Cardinal%20Health%20logo%20under%20a%20magnifying%20glass_%20By%20Casimiro.jpeg)
As Cardinal Health has outpaced relative to the broader market over the past year, Wall Street analysts maintain a strongly optimistic outlook about the stock’s prospects.
/Merck%20%26%20Co%20Inc%20HQ%20-by%20Sundry%20Photography%20via%20iStock.jpg)
Merck has outperformed the broader market over the past year, and analysts remain optimistic about the stock.
/Abbott%20Laboratories%20HQ%20photo-%20by%20Sundry%20Photography%20via%20iStock.jpg)
Abbott has lagged behind the broader market over the past year, yet analysts remain highly bullish about the stock’s prospects.
Though Viatris has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.